The Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes has released final results for the year ending November 2015. The company has achieved and continues to achieve rapid progress against its strategic goals, on a modest and well funded budget. The company has signed six commercial agreements since December 2014 including deals with a large US multinational, KSF (Slimfast), and most recently Royal DSM, one of the world’s leading food ingredien
